Haleon PLC Sponsored ADR (NYSE:HLN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company.
A number of research firms have recently issued reports on HLN. Zacks Research raised Haleon from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Jefferies Financial Group restated a “buy” rating on shares of Haleon in a research note on Monday, August 24th. Rothschild & Co Redburn downgraded Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th.
Check Out Our Latest Analysis on HLN
Institutional Inflows and Outflows
Haleon Trading Down 2.7%
Haleon stock opened at $9.59 on Thursday. The stock has a 50-day simple moving average of $9.88 and a 200 day simple moving average of $9.76. The stock has a market capitalization of $42.18 billion, a P/E ratio of 24.59, a PEG ratio of 2.14 and a beta of 0.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.52 and a current ratio of 0.69. Haleon has a 52 week low of $8.65 and a 52 week high of $11.28.
Haleon Cuts Dividend
The business also recently announced a dividend, which will be paid on Thursday, September 17th. Investors of record on Friday, August 14th will be issued a dividend of $0.0642 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a dividend yield of 132.0%. Haleon’s payout ratio is presently 30.77%.
About Haleon
Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.
The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.
Further Reading
- Five stocks we like better than Haleon
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
